Unveils two new oral mucosal drug delivery systems, MOTS mucosal oral therapeutic system) for localized delivery and MOSTS system for systemic therapy. Both systems, which are in development, are based on the drug delivery firm's proprietary OROS osmotic pump oral drug delivery system, Alza Co-Chairman and CEO Martin Gerstel told an Alex. Brown health care conference in Baltimore May 8. MOTS/MOSTS overcome disadvantages of previously tried mucosal delivery methods, including lack of "system control" (dosage dumping), short duration of activity, and discomfort or inconvenience, Gerstel said.
You may also be interested in...
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
New medicines under evaluation at the European Medicines Agency.